Quarterly ResultAug 5, 2026, 07:08 AM
Q32 Bio Reports Positive Bempikibart Trial Results, $200M Offering
AI Summary
Q32 Bio Inc. reported its second quarter 2026 financial results and provided a corporate update. The company announced positive 36-week topline results from Part B of its SIGNAL-AA clinical trial for bempikibart, showing clinically meaningful efficacy in severe or very severe alopecia areata. Q32 Bio also completed a $200 million public offering in July 2026, extending its financial runway through Phase 3 topline results of its planned registration-directed program. The company reported a net loss of $8.9 million for the quarter.
Key Highlights
- Reported positive 36-week topline results for bempikibart in SIGNAL-AA Part B clinical trial.
- 40.0% of patients achieved a SALT-20 response at Week 36 in the mITT analysis.
- Completed a $200 million public offering in July 2026.
- Cash and cash equivalents were $106.3 million as of June 30, 2026.
- Financial runway expected through Phase 3 topline results of planned registration-directed program.
- Net loss was $8.9 million for the three months ended June 30, 2026.
- Research and development expenses decreased to $4.3 million for Q2 2026.
- General and administrative expenses increased to $4.9 million for Q2 2026.
Price Impact
More from QTTB